Premium
Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system
Author(s) -
Freudenthaler,
Schenck,
Lucht,
Gleiter
Publication year - 1999
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1999.00059.x
Subject(s) - fenoterol , losartan , angiotensin ii , erythropoietin , medicine , stimulation , endocrinology , renin–angiotensin system , pharmacology , antagonist , receptor , blood pressure , asthma
Aims The present study assessed the hypothesis that the β 2 sympathomimetic fenoterol influences the production of erythropoietin (EPO) by activation of the renin angiotensin system (RAS), i.e. angiotensin II.Methods In an open, parallel, randomized study healthy volunteers received i.v. either placebo (electrolyte solution), fenoterol or fenoterol in combination with an oral dose of the AT 1 ‐receptor antagonist losartan.Results Compared with placebo treatment AUC EPO (0,24 h) was significantly increased after fenoterol application by 48% whereas no increase in the group receiving fenoterol and losartan could be detected. The rise of PRA was statistically significant under fenoterol and fenoterol plus lorsartan.Conclusions Stimulation of EPO production during fenoterol infusion appears to be angiotensin II‐mediated. Thus, angiotensin II may be considered as one important physiological modulator of EPO production in humans.